Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have hypolipidemic and anti-inflammatory effects and may reduce the incidence of cerebrovascular disease and coronary artery disease. Although statins are generally well tolerated by most patients, they still have certain side effects, such as myalgia and, in severe cases, rhabdomyolysis. Theoretically, statins may induce or exacerbate symptoms of myasthenia gravis, but not by affecting neuromuscular junction transmission. Pharmacological studies have found that statins can inhibit T cell activation, induce the conversion of helper T (Th) cells to Th2 cells, act on B cells and cytokines, and reinforce B cell-mediated immune abnormalities, thus inducing the onset of disease or aggravating the disease by exacerbating the autoimmune response in patients with myasthenia gravis. To date, there have been several reports of exacerbation of symptoms in patients with autoimmune diseases after taking statins. In 2002, Parmar et al. reported a patient with myasthenia gravis symptoms after statin use, who developed eyelid ptosis and generalized weakness after 3 months of statin use, and the symptoms resolved after 6 weeks of discontinuation, and then reappeared with myasthenia gravis symptoms 2-3 months after taking the drugs again due to poor lipid control, and recovered after several weeks of discontinuation. This patient was diagnosed with myasthenia gravis, but his serology was negative for AchR antibodies and no repeat electrical stimulation was performed, so the diagnosis of MG was questioned. In 2008, Oh et al. reported that 54 of 170 patients with definite diagnosis of myasthenia gravis were taking statins, and 6 of them had worsening symptoms, all within the first 8 weeks after taking the drug. Jesse et al. also reported 2 cases of myasthenia gravis after taking statins. Both developed extraocular muscle palsy about 4 weeks after taking the drug and improved after stopping the statin and adjuvant low-dose hormone therapy. Although statins have the theoretical potential to exacerbate the disease and cases have been reported in reality, the drug is not an absolute contraindication and we should not choke on it. In patients with myasthenia gravis combined with hypercholesterolemia, statins should still be used as indicated. Doctors should inform patients of this possibility in advance and closely observe changes in myasthenia gravis and any other side effects while taking the drug, and adjust or discontinue statins as soon as they appear, so as to resolve the contradiction between the theory and reality of medication use.